You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNadolol
Accession NumberDB01203  (APRD00301)
TypeSmall Molecule
GroupsApproved
DescriptionA non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]
Structure
Thumb
Synonyms
Corgard
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Corgardtablet80 mg/1oralUs World Meds, Llc2016-04-01Not applicableUs
Corgardtablet40 mg/1oralPfizer Laboratories Div Pfizer Inc1979-12-10Not applicableUs
Corgardtablet80 mg/1oralPfizer Laboratories Div Pfizer Inc1979-12-10Not applicableUs
Corgardtablet20 mg/1oralUs World Meds, Llc2016-04-01Not applicableUs
Corgardtablet40 mg/1oralUs World Meds, Llc2016-04-01Not applicableUs
Corgardtablet20 mg/1oralPfizer Laboratories Div Pfizer Inc1979-12-10Not applicableUs
Corgard Tab 160mgtablet160 mgoralBristol Myers Squibb Canada1981-12-312004-10-29Canada
Corgard Tab 40mgtablet40 mgoralBristol Myers Squibb Canada1984-12-312006-05-29Canada
Corgard Tab 80mgtablet80 mgoralBristol Myers Squibb Canada1979-12-312006-10-25Canada
Nadololtablet20 mg/1oralGreenstone LLC2014-04-28Not applicableUs
Nadololtablet80 mgoralAa Pharma Inc1988-12-31Not applicableCanada
Nadololtablet40 mg/1oralGreenstone LLC2014-04-28Not applicableUs
Nadololtablet160 mgoralAa Pharma Inc1988-12-31Not applicableCanada
Nadololtablet80 mg/1oralGreenstone LLC2014-04-28Not applicableUs
Nadololtablet40 mgoralAa Pharma Inc1988-12-31Not applicableCanada
Nadolol-160 Tab 160mgtablet160 mgoralPro Doc Limitee1989-12-312014-07-24Canada
Nadolol-40 Tab 40mgtablet40 mgoralPro Doc Limitee1989-12-312015-07-10Canada
Nadolol-80 Tab 80mgtablet80 mgoralPro Doc Limitee1989-12-312015-07-10Canada
Ratio-nadolol Tab 160mgtablet160 mgoralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Ratio-nadolol Tab 40mgtablet40 mgoralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Ratio-nadolol Tab 80mgtablet80 mgoralRatiopharm Inc Division Of Teva Canada Limited1989-12-312006-08-04Canada
Teva-nadololtablet40 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Teva-nadololtablet80 mgoralTeva Canada Limited1994-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nadololtablet40 mg/1oralSandoz Inc2008-10-01Not applicableUs
Nadololtablet20 mg/1oralAmerican Health Packaging2014-04-14Not applicableUs
Nadololtablet20 mg/1oralTeva Pharmaceuticals USA Inc2008-11-03Not applicableUs
Nadololtablet40 mg/1oralMylan Institutional Inc.1994-07-12Not applicableUs
Nadololtablet40 mg/1oralCamber, Pharmaceuticals Inc2016-01-27Not applicableUs
Nadololtablet20 mg/1oralRebel Distributors Corp2008-10-01Not applicableUs
Nadololtablet20 mg/1oralAvera Mc Kennan Hospital2015-08-18Not applicableUs
Nadololtablet80 mg/1oralCipla USA Inc.2016-02-23Not applicableUs
Nadololtablet80 mg/1oralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs
Nadololtablet80 mg/1oralBlue Point Laboratories2014-02-05Not applicableUs
Nadololtablet80 mg/1oralSandoz Inc2008-10-01Not applicableUs
Nadololtablet40 mg/1oralAmerican Health Packaging2014-04-14Not applicableUs
Nadololtablet40 mg/1oralTeva Pharmaceuticals USA Inc2008-11-03Not applicableUs
Nadololtablet20 mg/1oralREMEDYREPACK INC.2013-02-22Not applicableUs
Nadololtablet80 mg/1oralCamber, Pharmaceuticals Inc2016-01-27Not applicableUs
Nadololtablet20 mg/1oralRebel Distributors Corp2011-01-18Not applicableUs
Nadololtablet20 mg/1oralAmerican Health Packaging2014-04-012015-12-31Us
Nadololtablet40 mg/1oralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs
Nadololtablet40 mg/1oralBlue Point Laboratories2014-02-05Not applicableUs
Nadololtablet40 mg/1oralRebel Distributors Corp2008-10-01Not applicableUs
Nadololtablet80 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Nadololtablet80 mg/1oralTeva Pharmaceuticals USA Inc2008-11-03Not applicableUs
Nadololtablet40 mg/1oralPhysicians Total Care, Inc.2010-01-14Not applicableUs
Nadololtablet20 mg/1oralCipla USA Inc.2016-02-23Not applicableUs
Nadololtablet40 mg/1oralRebel Distributors Corp2011-01-18Not applicableUs
Nadololtablet40 mg/1oralAmerican Health Packaging2014-04-012015-12-31Us
Nadololtablet20 mg/1oralBlue Point Laboratories2014-02-05Not applicableUs
Nadololtablet20 mg/1oralSandoz Inc2008-10-01Not applicableUs
Nadololtablet80 mg/1oralRebel Distributors Corp2008-10-01Not applicableUs
Nadololtablet40 mg/1oralDispensing Solutions, Inc.2008-10-01Not applicableUs
Nadololtablet40 mg/1oralCipla USA Inc.2016-02-23Not applicableUs
Nadololtablet20 mg/1oralMylan Pharmaceuticals Inc.1993-10-31Not applicableUs
Nadololtablet20 mg/1oralPhysicians Total Care, Inc.2005-05-16Not applicableUs
Nadololtablet20 mg/1oralCamber, Pharmaceuticals Inc2016-01-27Not applicableUs
Nadololtablet20 mg/1oralMylan Institutional Inc.1994-07-12Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnabetNot Available
SolgolNot Available
Brand mixtures
NameLabellerIngredients
CorzidePfizer Laboratories Div Pfizer Inc
Corzide Tab W Nadolol 40mgSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Corzide Tab W Nadolol 80mgSquibb Canada Inc., Division Of Bristol Myers Squibb Canada Inc.
Nadolol and BendroflumethiazideImpax Generics
SaltsNot Available
Categories
UNIIFEN504330V
CAS number42200-33-9
WeightAverage: 309.4006
Monoisotopic: 309.194008357
Chemical FormulaC17H27NO4
InChI KeyInChIKey=VWPOSFSPZNDTMJ-UCWKZMIHSA-N
InChI
InChI=1S/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1
IUPAC Name
(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol
SMILES
CC(C)(C)NCC(O)COC1=CC=CC2=C1C[[email protected]](O)[[email protected]](O)C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetralins. These are polycyclic aromatic compounds containing a tetralin moiety, which consists of a benzene fused to a cyclohexane.
KingdomOrganic compounds
Super ClassBenzenoids
ClassTetralins
Sub ClassNot Available
Direct ParentTetralins
Alternative Parents
Substituents
  • Tetralin
  • Alkyl aryl ether
  • Secondary alcohol
  • 1,2-diol
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension.
PharmacodynamicsNadolol is a nonselective beta-adrenergic receptor antagonist with a long half-life, and is structurally similar to propranolol. Clinical pharmacology studies have demonstrated beta-blocking activity by showing (1) reduction in heart rate and cardiac output at rest and on exercise, (2) reduction of systolic and diastolic blood pressure at rest and on exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. Nadolol has no intrinsic sympathomimetic activity and, unlike some other beta-adrenergic blocking agents, nadolol has little direct myocardial depressant activity and does not have an anesthetic-like membrane-stabilizing action.
Mechanism of actionLike other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively.
Related Articles
AbsorptionAbsorption of nadolol after oral dosing is variable, averaging about 30 percent.
Volume of distributionNot Available
Protein binding30%
Metabolism

Not metabolized by the liver and excreted unchanged primarily by the kidneys.

Route of eliminationUnlike many other beta-adrenergic blocking agents, nadolol is not metabolized by the liver and is excreted unchanged, principally by the kidneys. Nadolol is excreted predominantly in the urine.
Half life14-24 hours
ClearanceNot Available
ToxicityOral, mouse: LD50 = 4500mg/kg. Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nadolol Action PathwayDrug actionSMP00303
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9788
Blood Brain Barrier-0.966
Caco-2 permeable-0.8957
P-glycoprotein substrateSubstrate0.8317
P-glycoprotein inhibitor IInhibitor0.6192
P-glycoprotein inhibitor IINon-inhibitor0.7842
Renal organic cation transporterNon-inhibitor0.8736
CYP450 2C9 substrateNon-substrate0.7934
CYP450 2D6 substrateSubstrate0.7284
CYP450 3A4 substrateNon-substrate0.5456
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9106
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8072
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8934
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.7972 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9455
hERG inhibition (predictor II)Inhibitor0.5781
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral160 mg
Tabletoral20 mg/1
Tabletoral40 mg/1
Tabletoral80 mg/1
Tabletoral40 mg
Tabletoral80 mg
Prices
Unit descriptionCostUnit
Nadolol powder94.8USD g
Corgard 160 mg tablet4.4USD tablet
Corgard 80 mg tablet4.33USD tablet
Corgard 120 mg tablet3.96USD tablet
Corgard 40 mg tablet3.11USD tablet
Corgard 20 mg tablet3.04USD tablet
Nadolol 160 mg tablet2.25USD tablet
Nadolol 80 mg tablet1.45USD tablet
Apo-Nadol 160 mg Tablet1.26USD tablet
Nadolol 40 mg tablet1.07USD tablet
Naldol 80 mg tablet1.03USD tablet
Nadolol 20 mg tablet0.92USD tablet
Apo-Nadol 80 mg Tablet0.37USD tablet
Novo-Nadolol 80 mg Tablet0.37USD tablet
Apo-Nadol 40 mg Tablet0.26USD tablet
Novo-Nadolol 40 mg Tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point124-136 °CPhysProp
water solubility8330 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP0.81SANGSTER (1994)
Caco2 permeability-5.41ADME Research, USCD
pKa9.67MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility2.25 mg/mLALOGPS
logP1.23ALOGPS
logP0.87ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)13.59ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area81.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85.53 m3·mol-1ChemAxon
Polarizability34.63 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US3935267
General ReferencesNot Available
External Links
ATC CodesC07AA12C07BA12
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (74.1 KB)
Interactions
Drug Interactions
Drug
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Nadolol.
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Nadolol.
AcebutololAcebutolol may increase the hypotensive activities of Nadolol.
AceclofenacAceclofenac may decrease the antihypertensive activities of Nadolol.
AcepromazineAcepromazine may increase the hypotensive activities of Nadolol.
AcetaminophenThe serum concentration of Nadolol can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Nadolol.
AcetohexamideNadolol may increase the hypoglycemic activities of Acetohexamide.
AcetylcholineThe risk or severity of adverse effects can be increased when Nadolol is combined with Acetylcholine.
AcetyldigitoxinNadolol may increase the bradycardic activities of Acetyldigitoxin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Nadolol.
AdapaleneAdapalene may decrease the antihypertensive activities of Nadolol.
AfatinibThe serum concentration of Nadolol can be increased when it is combined with Afatinib.
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Nadolol.
AlbendazoleThe serum concentration of Nadolol can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.
AldosteroneThe serum concentration of Nadolol can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Nadolol can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Nadolol can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nadolol.
AlfuzosinNadolol may increase the orthostatic hypotensive activities of Alfuzosin.
AlimemazineAlimemazine may increase the hypotensive activities of Nadolol.
AliskirenNadolol may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Nadolol.
AmantadineThe serum concentration of Nadolol can be increased when it is combined with Amantadine.
AmbenoniumAmbenonium may increase the bradycardic activities of Nadolol.
AmbrisentanNadolol may increase the hypotensive activities of Ambrisentan.
AmifostineNadolol may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nadolol.
Aminohippuric acidThe serum concentration of Nadolol can be increased when it is combined with Aminohippuric acid.
AminophyllineNadolol may decrease the bronchodilatory activities of Aminophylline.
AmiodaroneAmiodarone may increase the bradycardic activities of Nadolol.
AmitriptylineThe serum concentration of Nadolol can be increased when it is combined with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Nadolol.
AmobarbitalAmobarbital may increase the hypotensive activities of Nadolol.
AmodiaquineThe metabolism of Nadolol can be decreased when combined with Amodiaquine.
AmoxapineThe serum concentration of Nadolol can be increased when it is combined with Amoxapine.
AmprenavirThe serum concentration of Nadolol can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Nadolol can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Nadolol is combined with Amyl Nitrite.
AntipyrineAntipyrine may decrease the antihypertensive activities of Nadolol.
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Nadolol.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nadolol.
ApremilastApremilast may decrease the antihypertensive activities of Nadolol.
ArbutamineNadolol may decrease the bronchodilatory activities of Arbutamine.
ArecolineThe risk or severity of adverse effects can be increased when Nadolol is combined with Arecoline.
ArformoterolNadolol may decrease the bronchodilatory activities of Arformoterol.
AripiprazoleAripiprazole may increase the hypotensive activities of Nadolol.
AstemizoleThe serum concentration of Nadolol can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Nadolol can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Nadolol.
AtorvastatinThe serum concentration of Nadolol can be increased when it is combined with Atorvastatin.
AzapropazoneAzapropazone may decrease the antihypertensive activities of Nadolol.
AzelastineAzelastine may decrease the antihypertensive activities of Nadolol.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nadolol is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Nadolol can be increased when it is combined with Azithromycin.
BalsalazideBalsalazide may decrease the antihypertensive activities of Nadolol.
BambuterolNadolol may decrease the bronchodilatory activities of Bambuterol.
BarbitalBarbital may increase the hypotensive activities of Nadolol.
BenazeprilBenazepril may increase the hypotensive activities of Nadolol.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Nadolol.
BenmoxinBenmoxin may increase the hypotensive activities of Nadolol.
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Nadolol.
BenzocaineThe serum concentration of Nadolol can be increased when it is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.
BepridilNadolol may increase the hypotensive activities of Bepridil.
BeractantNadolol may increase the bradycardic activities of Beractant.
BetaxololBetaxolol may increase the hypotensive activities of Nadolol.
BethanecholThe risk or severity of adverse effects can be increased when Nadolol is combined with Bethanechol.
BethanidineBethanidine may increase the hypotensive activities of Nadolol.
BimatoprostBimatoprost may increase the hypotensive activities of Nadolol.
BiperidenThe serum concentration of Nadolol can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Nadolol.
BosentanBosentan may increase the hypotensive activities of Nadolol.
BosutinibThe serum concentration of Nadolol can be increased when it is combined with Bosutinib.
BretyliumBretylium may increase the bradycardic activities of Nadolol.
BretyliumNadolol may increase the hypotensive activities of Bretylium.
BrimonidineNadolol may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Nadolol.
BromfenacBromfenac may decrease the antihypertensive activities of Nadolol.
BromocriptineNadolol may increase the vasoconstricting activities of Bromocriptine.
BromocriptineThe serum concentration of Nadolol can be increased when it is combined with Bromocriptine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nadolol.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Nadolol.
BupranololNadolol may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Nadolol can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Nadolol can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Nadolol can be increased when it is combined with Cabazitaxel.
CabergolineNadolol may increase the vasoconstricting activities of Cabergoline.
CaffeineThe serum concentration of Nadolol can be increased when it is combined with Caffeine.
CalfactantNadolol may increase the bradycardic activities of Calfactant.
CanagliflozinThe risk or severity of adverse effects can be increased when Nadolol is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Nadolol.
CandoxatrilCandoxatril may increase the hypotensive activities of Nadolol.
CaptoprilCaptopril may increase the hypotensive activities of Nadolol.
CarbacholThe risk or severity of adverse effects can be increased when Nadolol is combined with Carbachol.
CarbamazepineThe serum concentration of Nadolol can be decreased when it is combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Nadolol.
CarprofenCarprofen may decrease the antihypertensive activities of Nadolol.
CarteololCarteolol may increase the hypotensive activities of Nadolol.
CarvedilolCarvedilol may increase the hypotensive activities of Nadolol.
CaspofunginThe serum concentration of Nadolol can be increased when it is combined with Caspofungin.
CastanospermineCastanospermine may decrease the antihypertensive activities of Nadolol.
CelecoxibCelecoxib may decrease the antihypertensive activities of Nadolol.
CeliprololCeliprolol may increase the hypotensive activities of Nadolol.
CeliprololNadolol may decrease the bronchodilatory activities of Celiprolol.
CeritinibNadolol may increase the bradycardic activities of Ceritinib.
CevimelineThe risk or severity of adverse effects can be increased when Nadolol is combined with Cevimeline.
ChloroquineChloroquine may decrease the antihypertensive activities of Nadolol.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Nadolol.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Nadolol.
ChlorpropamideNadolol may increase the hypoglycemic activities of Chlorpropamide.
ChlorpropamideThe serum concentration of Nadolol can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Nadolol can be increased when it is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nadolol.
CholesterolThe serum concentration of Nadolol can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Nadolol can be decreased when it is combined with Cholic Acid.
CilazaprilNadolol may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Nadolol can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Nadolol can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Nadolol can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Nadolol can be increased when it is combined with Clarithromycin.
ClenbuterolNadolol may decrease the bronchodilatory activities of Clenbuterol.
ClevidipineThe risk or severity of adverse effects can be increased when Nadolol is combined with Clevidipine.
ClofazimineThe serum concentration of Nadolol can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Nadolol can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Nadolol.
ClonixinClonixin may decrease the antihypertensive activities of Nadolol.
ClotrimazoleThe serum concentration of Nadolol can be decreased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Nadolol can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Nadolol can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Nadolol can be increased when it is combined with Colforsin.
CoumaphosCoumaphos may increase the bradycardic activities of Nadolol.
CrizotinibThe serum concentration of Nadolol can be increased when it is combined with Crizotinib.
CrizotinibNadolol may increase the bradycardic activities of Crizotinib.
CryptenamineCryptenamine may increase the hypotensive activities of Nadolol.
CyclophosphamideThe serum concentration of Nadolol can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Nadolol can be decreased when it is combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Nadolol.
D-LimoneneD-Limonene may decrease the antihypertensive activities of Nadolol.
DaclatasvirThe serum concentration of Nadolol can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Nadolol can be increased when it is combined with Dactinomycin.
DapagliflozinThe risk or severity of adverse effects can be increased when Nadolol is combined with Dapagliflozin.
DapoxetineThe serum concentration of Nadolol can be increased when it is combined with Dapoxetine.
DasatinibThe serum concentration of Nadolol can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Nadolol can be decreased when it is combined with Daunorubicin.
DebrisoquinNadolol may increase the hypotensive activities of Debrisoquin.
DecamethoniumDecamethonium may increase the bradycardic activities of Nadolol.
DemecariumDemecarium may increase the bradycardic activities of Nadolol.
DeserpidineNadolol may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Nadolol can be increased when it is combined with Desipramine.
DeslanosideNadolol may increase the bradycardic activities of Deslanoside.
DesloratadineThe serum concentration of Nadolol can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Nadolol can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Nadolol.
DextromethorphanThe serum concentration of Nadolol can be increased when it is combined with Dextromethorphan.
DiazoxideDiazoxide may increase the hypotensive activities of Nadolol.
DichlorvosDichlorvos may increase the bradycardic activities of Nadolol.
DiclofenacDiclofenac may decrease the antihypertensive activities of Nadolol.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nadolol.
DiflunisalDiflunisal may decrease the antihypertensive activities of Nadolol.
DigitoxinNadolol may increase the bradycardic activities of Digitoxin.
DigoxinNadolol may increase the bradycardic activities of Digoxin.
DigoxinThe serum concentration of Nadolol can be decreased when it is combined with Digoxin.
DihydroergotamineNadolol may increase the vasoconstricting activities of Dihydroergotamine.
DihydroergotamineThe serum concentration of Nadolol can be increased when it is combined with Dihydroergotamine.
DiltiazemDiltiazem may increase the hypotensive activities of Nadolol.
DinutuximabThe risk or severity of adverse effects can be increased when Nadolol is combined with Dinutuximab.
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Nadolol.
DipivefrinNadolol may decrease the bronchodilatory activities of Dipivefrin.
DipyridamoleDipyridamole may increase the bradycardic activities of Nadolol.
DipyridamoleThe risk or severity of adverse effects can be increased when Nadolol is combined with Dipyridamole.
DisopyramideDisopyramide may increase the bradycardic activities of Nadolol.
DobutamineNadolol may decrease the bronchodilatory activities of Dobutamine.
DonepezilDonepezil may increase the bradycardic activities of Nadolol.
DorzolamideDorzolamide may increase the hypotensive activities of Nadolol.
DoxazosinDoxazosin may increase the hypotensive activities of Nadolol.
DoxepinThe serum concentration of Nadolol can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Nadolol can be decreased when it is combined with Doxorubicin.
DronabinolThe serum concentration of Nadolol can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Nadolol can be increased when it is combined with Dronedarone.
DronedaroneNadolol may increase the bradycardic activities of Dronedarone.
DroxicamDroxicam may decrease the antihypertensive activities of Nadolol.
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Nadolol.
DroxidopaNadolol may decrease the bronchodilatory activities of Droxidopa.
DuloxetineNadolol may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineNadolol may decrease the bronchodilatory activities of Dyphylline.
EchothiophateEchothiophate may increase the bradycardic activities of Nadolol.
EdrophoniumEdrophonium may increase the bradycardic activities of Nadolol.
EfonidipineNadolol may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Nadolol can be increased when it is combined with Elbasvir.
EmpagliflozinThe risk or severity of adverse effects can be increased when Nadolol is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Nadolol.
EnalaprilatNadolol may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Nadolol can be increased when it is combined with Enzalutamide.
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Nadolol.
EphedraNadolol may decrease the bronchodilatory activities of Ephedra.
EPIBATIDINEThe risk or severity of adverse effects can be increased when Nadolol is combined with EPIBATIDINE.
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Nadolol.
EpinephrineNadolol may decrease the bronchodilatory activities of Epinephrine.
EpirizoleEpirizole may decrease the antihypertensive activities of Nadolol.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nadolol.
EpoprostenolNadolol may increase the hypotensive activities of Epoprostenol.
EprosartanEprosartan may increase the hypotensive activities of Nadolol.
Ergoloid mesylateNadolol may increase the vasoconstricting activities of Ergoloid mesylate.
ErgonovineNadolol may increase the vasoconstricting activities of Ergonovine.
ErgonovineThe serum concentration of Nadolol can be increased when it is combined with Ergonovine.
ErgotamineNadolol may increase the vasoconstricting activities of Ergotamine.
ErgotamineThe serum concentration of Nadolol can be increased when it is combined with Ergotamine.
ErythromycinThe serum concentration of Nadolol can be decreased when it is combined with Erythromycin.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nadolol.
EstramustineThe serum concentration of Nadolol can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Nadolol can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Nadolol can be decreased when it is combined with Estrone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nadolol.
EtanerceptEtanercept may decrease the antihypertensive activities of Nadolol.
EtodolacEtodolac may decrease the antihypertensive activities of Nadolol.
EtofenamateEtofenamate may decrease the antihypertensive activities of Nadolol.
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Nadolol.
EtoperidoneThe serum concentration of Nadolol can be increased when it is combined with Etoperidone.
EtoposideThe serum concentration of Nadolol can be increased when it is combined with Etoposide.
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Nadolol.
EtravirineThe serum concentration of Nadolol can be increased when it is combined with Etravirine.
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Nadolol.
exisulindexisulind may decrease the antihypertensive activities of Nadolol.
FelodipineFelodipine may increase the hypotensive activities of Nadolol.
FenbufenFenbufen may decrease the antihypertensive activities of Nadolol.
FenfluramineThe serum concentration of Nadolol can be increased when it is combined with Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Nadolol.
FenoprofenFenoprofen may decrease the antihypertensive activities of Nadolol.
FenoterolNadolol may decrease the bronchodilatory activities of Fenoterol.
FentanylThe serum concentration of Nadolol can be increased when it is combined with Fentanyl.
FenthionFenthion may increase the bradycardic activities of Nadolol.
FexofenadineThe serum concentration of Nadolol can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Nadolol can be increased when it is combined with Fidaxomicin.
FingolimodNadolol may increase the bradycardic activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nadolol.
FluconazoleThe serum concentration of Nadolol can be increased when it is combined with Fluconazole.
FlunixinFlunixin may decrease the antihypertensive activities of Nadolol.
FluoxetineThe serum concentration of Nadolol can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Nadolol can be increased when it is combined with Flupentixol.
FluphenazineFluphenazine may increase the hypotensive activities of Nadolol.
FlurazepamThe serum concentration of Nadolol can be increased when it is combined with Flurazepam.
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Nadolol.
FluvoxamineThe serum concentration of Nadolol can be increased when it is combined with Fluvoxamine.
FormoterolNadolol may decrease the bronchodilatory activities of Formoterol.
FosinoprilFosinopril may increase the hypotensive activities of Nadolol.
FurazolidoneFurazolidone may increase the hypotensive activities of Nadolol.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nadolol.
GalantamineGalantamine may increase the bradycardic activities of Nadolol.
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Nadolol.
GefitinibThe serum concentration of Nadolol can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Nadolol can be increased when it is combined with Genistein.
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Nadolol.
GlibornurideNadolol may increase the hypoglycemic activities of Glibornuride.
GliclazideNadolol may increase the hypoglycemic activities of Gliclazide.
GlimepirideNadolol may increase the hypoglycemic activities of Glimepiride.
GlipizideNadolol may increase the hypoglycemic activities of Glipizide.
GliquidoneNadolol may increase the hypoglycemic activities of Gliquidone.
GlisoxepideNadolol may increase the hypoglycemic activities of Glisoxepide.
GlyburideNadolol may increase the hypoglycemic activities of Glyburide.
GlyburideThe serum concentration of Nadolol can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Nadolol can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Nadolol can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Nadolol can be increased when it is combined with Grepafloxacin.
GTS-21The risk or severity of adverse effects can be increased when Nadolol is combined with GTS-21.
GuanabenzGuanabenz may increase the hypotensive activities of Nadolol.
GuanadrelGuanadrel may increase the hypotensive activities of Nadolol.
GuanethidineGuanethidine may increase the hypotensive activities of Nadolol.
GuanfacineGuanfacine may increase the hypotensive activities of Nadolol.
HaloperidolThe serum concentration of Nadolol can be increased when it is combined with Haloperidol.
HexamethoniumNadolol may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Nadolol.
HMPL-004HMPL-004 may decrease the antihypertensive activities of Nadolol.
Huperzine AHuperzine A may increase the bradycardic activities of Nadolol.
HydracarbazineHydracarbazine may increase the hypotensive activities of Nadolol.
HydralazineNadolol may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Nadolol.
HydrocortisoneThe serum concentration of Nadolol can be increased when it is combined with Hydrocortisone.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nadolol.
HydroxychloroquineThe metabolism of Nadolol can be decreased when combined with Hydroxychloroquine.
IbuprofenIbuprofen may decrease the antihypertensive activities of Nadolol.
IbuproxamIbuproxam may decrease the antihypertensive activities of Nadolol.
IcatibantIcatibant may decrease the antihypertensive activities of Nadolol.
IdelalisibThe serum concentration of Nadolol can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Nadolol.
ImatinibThe serum concentration of Nadolol can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Nadolol can be increased when it is combined with Imipramine.
IndacaterolNadolol may decrease the bronchodilatory activities of Indacaterol.
IndalpineThe serum concentration of Nadolol can be increased when it is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Nadolol.
IndenololNadolol may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Nadolol can be decreased when it is combined with Indinavir.
IndomethacinIndomethacin may decrease the antihypertensive activities of Nadolol.
IndoprofenIndoprofen may decrease the antihypertensive activities of Nadolol.
IndoraminNadolol may increase the hypotensive activities of Indoramin.
Insulin PorkNadolol may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypotensive activities of Nadolol.
IproniazidIproniazid may increase the hypotensive activities of Nadolol.
IrbesartanIrbesartan may increase the hypotensive activities of Nadolol.
IsavuconazoniumThe serum concentration of Nadolol can be increased when it is combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nadolol.
IsoetarineNadolol may decrease the bronchodilatory activities of Isoetarine.
IsoflurophateIsoflurophate may increase the bradycardic activities of Nadolol.
IsoprenalineNadolol may decrease the bronchodilatory activities of Isoprenaline.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nadolol.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nadolol.
IsoxicamIsoxicam may decrease the antihypertensive activities of Nadolol.
IsoxsuprineThe risk or severity of adverse effects can be increased when Nadolol is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Nadolol.
ItraconazoleThe serum concentration of Nadolol can be increased when it is combined with Itraconazole.
IvabradineNadolol may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Nadolol can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Nadolol can be increased when it is combined with Ivermectin.
KebuzoneKebuzone may decrease the antihypertensive activities of Nadolol.
KetamineThe serum concentration of Nadolol can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Nadolol can be increased when it is combined with Ketoconazole.
KetoprofenKetoprofen may decrease the antihypertensive activities of Nadolol.
KetorolacKetorolac may decrease the antihypertensive activities of Nadolol.
LabetalolLabetalol may increase the hypotensive activities of Nadolol.
LacidipineNadolol may increase the hypotensive activities of Lacidipine.
LacosamideNadolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LanreotideNadolol may increase the bradycardic activities of Lanreotide.
LansoprazoleThe serum concentration of Nadolol can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Nadolol can be increased when it is combined with Lapatinib.
LatanoprostLatanoprost may increase the hypotensive activities of Nadolol.
LeflunomideLeflunomide may decrease the antihypertensive activities of Nadolol.
LercanidipineLercanidipine may increase the hypotensive activities of Nadolol.
LevobunololThe risk or severity of adverse effects can be increased when Nadolol is combined with Levobunolol.
LevodopaNadolol may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Nadolol can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Nadolol can be increased when it is combined with Levomilnacipran.
LevothyroxineThe serum concentration of Nadolol can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Nadolol.
LiothyronineThe serum concentration of Nadolol can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Nadolol can be decreased when it is combined with Liotrix.
LisinoprilLisinopril may increase the hypotensive activities of Nadolol.
LobelineThe risk or severity of adverse effects can be increased when Nadolol is combined with Lobeline.
LofexidineNadolol may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Nadolol can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Nadolol can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Nadolol can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Nadolol can be increased when it is combined with Loratadine.
LornoxicamLornoxicam may decrease the antihypertensive activities of Nadolol.
LosartanLosartan may increase the hypotensive activities of Nadolol.
LovastatinThe serum concentration of Nadolol can be increased when it is combined with Lovastatin.
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Nadolol.
Lu AA21004The serum concentration of Nadolol can be increased when it is combined with Lu AA21004.
LucinactantNadolol may increase the bradycardic activities of Lucinactant.
LumacaftorThe serum concentration of Nadolol can be decreased when it is combined with Lumacaftor.
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Nadolol.
MacitentanNadolol may increase the hypotensive activities of Macitentan.
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Nadolol.
MalathionMalathion may increase the bradycardic activities of Nadolol.
ManidipineNadolol may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nadolol.
MaprotilineThe serum concentration of Nadolol can be increased when it is combined with Maprotiline.
MasoprocolMasoprocol may decrease the antihypertensive activities of Nadolol.
MebanazineMebanazine may increase the hypotensive activities of Nadolol.
MebendazoleThe serum concentration of Nadolol can be increased when it is combined with Mebendazole.
MecamylamineMecamylamine may increase the hypotensive activities of Nadolol.
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Nadolol.
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Nadolol.
MefloquineMefloquine may increase the bradycardic activities of Nadolol.
Megestrol acetateThe serum concentration of Nadolol can be increased when it is combined with Megestrol acetate.
MeloxicamMeloxicam may decrease the antihypertensive activities of Nadolol.
MemantineMemantine may increase the bradycardic activities of Nadolol.
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Nadolol.
MeprobamateThe serum concentration of Nadolol can be increased when it is combined with Meprobamate.
MesalazineMesalazine may decrease the antihypertensive activities of Nadolol.
MesoridazineMesoridazine may increase the hypotensive activities of Nadolol.
MetamizoleMetamizole may decrease the antihypertensive activities of Nadolol.
MethacholineThe risk or severity of adverse effects can be increased when Nadolol is combined with Methacholine.
MethadoneThe serum concentration of Nadolol can be increased when it is combined with Methadone.
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nadolol.
MethohexitalMethohexital may increase the hypotensive activities of Nadolol.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Nadolol.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nadolol.
MethyldopaMethyldopa may increase the hypotensive activities of Nadolol.
Methylene blueMethylene blue may increase the hypotensive activities of Nadolol.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nadolol.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nadolol.
MetipranololNadolol may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Nadolol.
MetoprololMetoprolol may increase the hypotensive activities of Nadolol.
MibefradilNadolol may increase the hypotensive activities of Mibefradil.
MiconazoleThe serum concentration of Nadolol can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Nadolol can be decreased when it is combined with Midazolam.
MidodrineNadolol may increase the bradycardic activities of Midodrine.
MifepristoneThe serum concentration of Nadolol can be decreased when it is combined with Mifepristone.
MilnacipranThe serum concentration of Nadolol can be increased when it is combined with Milnacipran.
MinaprineMinaprine may increase the bradycardic activities of Nadolol.
MinoxidilMinoxidil may increase the hypotensive activities of Nadolol.
MitomycinThe serum concentration of Nadolol can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Nadolol can be decreased when it is combined with Mitoxantrone.
MoclobemideMoclobemide may increase the hypotensive activities of Nadolol.
MoexiprilMoexipril may increase the hypotensive activities of Nadolol.
MolsidomineMolsidomine may increase the hypotensive activities of Nadolol.
MoricizineMoricizine may increase the hypotensive activities of Nadolol.
MorphineThe serum concentration of Nadolol can be increased when it is combined with Morphine.
MoxonidineNadolol may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Nadolol.
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Nadolol.
NabumetoneNabumetone may decrease the antihypertensive activities of Nadolol.
NaftifineNaftifine may decrease the antihypertensive activities of Nadolol.
NaltrexoneThe serum concentration of Nadolol can be increased when it is combined with Naltrexone.
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.
NaproxenNaproxen may decrease the antihypertensive activities of Nadolol.
NaringeninThe serum concentration of Nadolol can be increased when it is combined with Naringenin.
NCX 4016NCX 4016 may decrease the antihypertensive activities of Nadolol.
NebivololNadolol may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nadolol can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Nadolol can be decreased when it is combined with Nelfinavir.
NeostigmineNeostigmine may increase the bradycardic activities of Nadolol.
NepafenacNepafenac may decrease the antihypertensive activities of Nadolol.
NesiritideThe risk or severity of adverse effects can be increased when Nadolol is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Nadolol.
NicardipineNicardipine may increase the hypotensive activities of Nadolol.
NicorandilNicorandil may increase the hypotensive activities of Nadolol.
NicotineThe risk or severity of adverse effects can be increased when Nadolol is combined with Nicotine.
Nicotine bitartrateThe risk or severity of adverse effects can be increased when Nadolol is combined with Nicotine bitartrate.
NifedipineNifedipine may increase the hypotensive activities of Nadolol.
NifedipineThe risk or severity of adverse effects can be increased when Nadolol is combined with Nifedipine.
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Nadolol.
NiguldipineNadolol may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nadolol can be increased when it is combined with Nilotinib.
NilvadipineNadolol may increase the hypotensive activities of Nilvadipine.
NimesulideNimesulide may decrease the antihypertensive activities of Nadolol.
NimodipineNimodipine may increase the hypotensive activities of Nadolol.
NisoldipineNisoldipine may increase the hypotensive activities of Nadolol.
NitrazepamThe serum concentration of Nadolol can be increased when it is combined with Nitrazepam.
NitrendipineNitrendipine may increase the hypotensive activities of Nadolol.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nadolol.
NitroprussideNitroprusside may increase the hypotensive activities of Nadolol.
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Nadolol.
NorepinephrineNadolol may decrease the bronchodilatory activities of Norepinephrine.
NorethisteroneThe serum concentration of Nadolol can be decreased when it is combined with Norethisterone.
ObinutuzumabNadolol may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Nadolol.
OctreotideOctreotide may increase the bradycardic activities of Nadolol.
OlanzapineThe serum concentration of Nadolol can be increased when it is combined with Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Nadolol.
OlodaterolNadolol may decrease the bronchodilatory activities of Olodaterol.
OlopatadineOlopatadine may decrease the antihypertensive activities of Nadolol.
OlsalazineOlsalazine may decrease the antihypertensive activities of Nadolol.
OmapatrilatOmapatrilat may increase the hypotensive activities of Nadolol.
OmeprazoleThe serum concentration of Nadolol can be increased when it is combined with Omeprazole.
OrciprenalineNadolol may decrease the bronchodilatory activities of Orciprenaline.
OrgoteinOrgotein may decrease the antihypertensive activities of Nadolol.
OuabainNadolol may increase the bradycardic activities of Ouabain.
OxaprozinOxaprozin may decrease the antihypertensive activities of Nadolol.
OxprenololNadolol may increase the hypotensive activities of Oxprenolol.
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Nadolol.
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Nadolol.
P-NitrophenolThe serum concentration of Nadolol can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Nadolol can be increased when it is combined with Paclitaxel.
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Nadolol.
Palmitic AcidThe serum concentration of Nadolol can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Nadolol can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nadolol.
ParecoxibParecoxib may decrease the antihypertensive activities of Nadolol.
PargylineNadolol may increase the hypotensive activities of Pargyline.
ParoxetineThe serum concentration of Nadolol can be increased when it is combined with Paroxetine.
PasireotideNadolol may increase the bradycardic activities of Pasireotide.
PenbutololNadolol may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Nadolol.
PentoliniumPentolinium may increase the hypotensive activities of Nadolol.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nadolol.
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Nadolol.
PerindoprilPerindopril may increase the hypotensive activities of Nadolol.
PerphenazinePerphenazine may increase the hypotensive activities of Nadolol.
PhenelzinePhenelzine may increase the hypotensive activities of Nadolol.
PheniprazinePheniprazine may increase the hypotensive activities of Nadolol.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nadolol.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nadolol.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nadolol.
PhentolaminePhentolamine may increase the hypotensive activities of Nadolol.
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Nadolol.
PhenylpropanolaminePhenylpropanolamine may increase the atrioventricular blocking (AV block) activities of Nadolol.
PhenylpropanolamineNadolol may decrease the bronchodilatory activities of Phenylpropanolamine.
PhysostigminePhysostigmine may increase the bradycardic activities of Nadolol.
PilocarpineThe risk or severity of adverse effects can be increased when Nadolol is combined with Pilocarpine.
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Nadolol.
PimozideThe serum concentration of Nadolol can be increased when it is combined with Pimozide.
PinacidilNadolol may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Nadolol.
PirbuterolNadolol may decrease the bronchodilatory activities of Pirbuterol.
PirfenidonePirfenidone may decrease the antihypertensive activities of Nadolol.
PirlindolePirlindole may increase the hypotensive activities of Nadolol.
PiroxicamPiroxicam may decrease the antihypertensive activities of Nadolol.
PivhydrazinePivhydrazine may increase the hypotensive activities of Nadolol.
Platelet Activating FactorThe serum concentration of Nadolol can be decreased when it is combined with Platelet Activating Factor.
PolythiazideNadolol may increase the hypotensive activities of Polythiazide.
PonatinibThe serum concentration of Nadolol can be increased when it is combined with Ponatinib.
Poractant alfaNadolol may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe serum concentration of Nadolol can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Nadolol can be increased when it is combined with Pravastatin.
PrazosinPrazosin may increase the hypotensive activities of Nadolol.
PrednisoneThe serum concentration of Nadolol can be increased when it is combined with Prednisone.
PrimaquineThe metabolism of Nadolol can be decreased when combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Nadolol.
ProbenecidThe serum concentration of Nadolol can be increased when it is combined with Probenecid.
ProcaterolNadolol may decrease the bronchodilatory activities of Procaterol.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Nadolol.
ProgesteroneThe serum concentration of Nadolol can be decreased when it is combined with Progesterone.
PromazinePromazine may increase the hypotensive activities of Nadolol.
PromethazinePromethazine may increase the hypotensive activities of Nadolol.
PropacetamolPropacetamol may decrease the antihypertensive activities of Nadolol.
PropafenoneThe serum concentration of Nadolol can be increased when it is combined with Propafenone.
PropafenoneNadolol may increase the bradycardic activities of Propafenone.
PropranololPropranolol may increase the hypotensive activities of Nadolol.
ProtriptylineThe serum concentration of Nadolol can be increased when it is combined with Protriptyline.
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Nadolol.
PTC299PTC299 may decrease the antihypertensive activities of Nadolol.
PyridostigminePyridostigmine may increase the bradycardic activities of Nadolol.
QuercetinThe serum concentration of Nadolol can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Nadolol is combined with Quetiapine.
QuinacrineThe serum concentration of Nadolol can be increased when it is combined with Quinacrine.
QuinaprilQuinapril may increase the hypotensive activities of Nadolol.
QuinidineThe serum concentration of Nadolol can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Nadolol.
RamiprilRamipril may increase the hypotensive activities of Nadolol.
RanitidineThe serum concentration of Nadolol can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Nadolol can be increased when it is combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Nadolol.
ReboxetineThe serum concentration of Nadolol can be increased when it is combined with Reboxetine.
RegorafenibRegorafenib may increase the bradycardic activities of Nadolol.
RemikirenRemikiren may increase the hypotensive activities of Nadolol.
RescinnamineNadolol may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Nadolol.
ResveratrolResveratrol may decrease the antihypertensive activities of Nadolol.
RifampicinThe serum concentration of Nadolol can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Nadolol can be increased when it is combined with Rilpivirine.
RiociguatNadolol may increase the hypotensive activities of Riociguat.
RisperidoneNadolol may increase the hypotensive activities of Risperidone.
RisperidoneRisperidone may increase the atrioventricular blocking (AV block) activities of Nadolol.
RitodrineNadolol may decrease the bronchodilatory activities of Ritodrine.
RitonavirThe serum concentration of Nadolol can be decreased when it is combined with Ritonavir.
RituximabNadolol may increase the hypotensive activities of Rituximab.
RivastigmineRivastigmine may increase the bradycardic activities of Nadolol.
RofecoxibRofecoxib may decrease the antihypertensive activities of Nadolol.
RolapitantThe serum concentration of Nadolol can be increased when it is combined with Rolapitant.
RopiniroleRopinirole may increase the atrioventricular blocking (AV block) activities of Nadolol.
RuxolitinibRuxolitinib may increase the bradycardic activities of Nadolol.
SafrazineSafrazine may increase the hypotensive activities of Nadolol.
SalbutamolNadolol may decrease the bronchodilatory activities of Salbutamol.
SalicylamideSalicylamide may decrease the antihypertensive activities of Nadolol.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Nadolol.
SalmeterolNadolol may decrease the bronchodilatory activities of Salmeterol.
SalsalateSalsalate may decrease the antihypertensive activities of Nadolol.
SaprisartanNadolol may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Nadolol can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Nadolol can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Nadolol.
SelegilineSelegiline may increase the hypotensive activities of Nadolol.
SelexipagNadolol may increase the hypotensive activities of Selexipag.
SeratrodastSeratrodast may decrease the antihypertensive activities of Nadolol.
SertralineThe serum concentration of Nadolol can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Nadolol.
SilodosinNadolol may increase the orthostatic hypotensive activities of Silodosin.
SimeprevirThe serum concentration of Nadolol can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Nadolol can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Nadolol can be decreased when it is combined with Sirolimus.
SitaxentanNadolol may increase the hypotensive activities of Sitaxentan.
SorafenibThe serum concentration of Nadolol can be increased when it is combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nadolol.
SpiraprilNadolol may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nadolol.
SRT501SRT501 may decrease the antihypertensive activities of Nadolol.
St. John's WortThe serum concentration of Nadolol can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Nadolol can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Nadolol can be decreased when it is combined with Streptozocin.
SufentanilSufentanil may increase the bradycardic activities of Nadolol.
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Nadolol.
SulfinpyrazoneThe serum concentration of Nadolol can be increased when it is combined with Sulfinpyrazone.
SulindacSulindac may decrease the antihypertensive activities of Nadolol.
SumatriptanThe serum concentration of Nadolol can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Nadolol can be increased when it is combined with Sunitinib.
SuprofenSuprofen may decrease the antihypertensive activities of Nadolol.
TacrineTacrine may increase the bradycardic activities of Nadolol.
TacrolimusThe serum concentration of Nadolol can be decreased when it is combined with Tacrolimus.
TadalafilTadalafil may increase the antihypertensive activities of Nadolol.
TamoxifenThe serum concentration of Nadolol can be decreased when it is combined with Tamoxifen.
TamsulosinNadolol may increase the orthostatic hypotensive activities of Tamsulosin.
Taurocholic AcidThe serum concentration of Nadolol can be increased when it is combined with Taurocholic Acid.
TelmisartanTelmisartan may increase the hypotensive activities of Nadolol.
TemocaprilNadolol may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Nadolol can be increased when it is combined with Temsirolimus.
TenoxicamTenoxicam may decrease the antihypertensive activities of Nadolol.
TepoxalinTepoxalin may decrease the antihypertensive activities of Nadolol.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Nadolol.
TerbutalineNadolol may decrease the bronchodilatory activities of Terbutaline.
TerfenadineThe serum concentration of Nadolol can be increased when it is combined with Terfenadine.
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Nadolol.
TerlipressinNadolol may increase the hypotensive activities of Terlipressin.
TesmilifeneThe serum concentration of Nadolol can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Nadolol can be increased when it is combined with Testosterone.
TheophyllineNadolol may decrease the bronchodilatory activities of Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Nadolol.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Nadolol.
ThiopentalThiopental may increase the hypotensive activities of Nadolol.
ThioridazineThioridazine may increase the hypotensive activities of Nadolol.
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Nadolol.
TiboloneNadolol may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Nadolol can be increased when it is combined with Ticagrelor.
TicrynafenNadolol may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Nadolol.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nadolol.
TofacitinibTofacitinib may increase the bradycardic activities of Nadolol.
TolazamideNadolol may increase the hypoglycemic activities of Tolazamide.
TolazolineTolazoline may increase the hypotensive activities of Nadolol.
TolbutamideNadolol may increase the hypoglycemic activities of Tolbutamide.
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Nadolol.
TolmetinTolmetin may decrease the antihypertensive activities of Nadolol.
ToloxatoneToloxatone may increase the hypotensive activities of Nadolol.
TolvaptanThe serum concentration of Nadolol can be increased when it is combined with Tolvaptan.
TorasemideTorasemide may increase the hypotensive activities of Nadolol.
TrandolaprilTrandolapril may increase the hypotensive activities of Nadolol.
TranilastTranilast may decrease the antihypertensive activities of Nadolol.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Nadolol.
TranylcypromineTranylcypromine may increase the hypotensive activities of Nadolol.
TravoprostTravoprost may increase the hypotensive activities of Nadolol.
TrazodoneThe serum concentration of Nadolol can be increased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Nadolol.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nadolol.
TrichlorfonTrichlorfon may increase the bradycardic activities of Nadolol.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nadolol.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Nadolol.
TriflupromazineTriflupromazine may increase the hypotensive activities of Nadolol.
TrimazosinNadolol may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Nadolol.
TrimethoprimThe serum concentration of Nadolol can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Nadolol can be increased when it is combined with Trimipramine.
Trisalicylate-cholineTrisalicylate-choline may decrease the antihypertensive activities of Nadolol.
TroleandomycinThe serum concentration of Nadolol can be increased when it is combined with Troleandomycin.
TubocurarineTubocurarine may increase the bradycardic activities of Nadolol.
UdenafilUdenafil may increase the antihypertensive activities of Nadolol.
UnoprostoneNadolol may increase the hypotensive activities of Unoprostone.
ValdecoxibValdecoxib may decrease the antihypertensive activities of Nadolol.
ValsartanValsartan may increase the hypotensive activities of Nadolol.
VardenafilVardenafil may increase the antihypertensive activities of Nadolol.
VareniclineThe risk or severity of adverse effects can be increased when Nadolol is combined with Varenicline.
VenlafaxineThe serum concentration of Nadolol can be increased when it is combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nadolol.
VilanterolNadolol may decrease the bronchodilatory activities of Vilanterol.
VilazodoneThe serum concentration of Nadolol can be increased when it is combined with Vilazodone.
VinblastineThe serum concentration of Nadolol can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Nadolol can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Nadolol can be increased when it is combined with Vinorelbine.
VortioxetineThe serum concentration of Nadolol can be increased when it is combined with Vortioxetine.
XylometazolineNadolol may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Nadolol.
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Nadolol.
ZileutonZileuton may decrease the antihypertensive activities of Nadolol.
ZimelidineThe serum concentration of Nadolol can be increased when it is combined with Zimelidine.
ZomepiracZomepirac may decrease the antihypertensive activities of Nadolol.
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Magnesium, potassium and zinc needs increased.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009 ]
  3. Koshiji M, Ito H, Minatoguchi S, Watanabe H, Imai Y, Kakami M, Hirakawa S: A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing. Clin Exp Pharmacol Physiol. 1992 Jul;19(7):481-8. [PubMed:1354084 ]
  4. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]
  5. Varma DR: Ligand-independent negative chronotropic responses of rat and mouse right atria to beta-adrenoceptor antagonists. Can J Physiol Pharmacol. 1999 Dec;77(12):943-9. [PubMed:10606440 ]
  6. Wheeldon NM, McDevitt DG, Lipworth BJ: Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol. 1994 Apr;37(4):363-9. [PubMed:7912539 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wheeldon NM, McDevitt DG, Lipworth BJ: The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1994 Aug;38(2):103-8. [PubMed:7981009 ]
  3. Ozakca I, Arioglu E, Guner S, Altan VM, Ozcelikay AT: Role of beta-3-adrenoceptor in catecholamine-induced relaxations in gastric fundus from control and diabetic rats. Pharmacology. 2007;80(4):227-38. Epub 2007 Jul 6. [PubMed:17622774 ]
  4. Liu YL, Toubro S, Astrup A, Stock MJ: Contribution of beta 3-adrenoceptor activation to ephedrine-induced thermogenesis in humans. Int J Obes Relat Metab Disord. 1995 Sep;19(9):678-85. [PubMed:8574280 ]
  5. Wheeldon NM, McDevitt DG, Lipworth BJ: Evaluation of in vivo partial beta 1/beta 2-agonist activity: a dose-ranging study with carteolol. Br J Clin Pharmacol. 1992 Apr;33(4):411-6. [PubMed:1349493 ]
  6. Varma DR, Shen H, Deng XF, Peri KG, Chemtob S, Mulay S: Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium. Br J Pharmacol. 1999 Jun;127(4):895-902. [PubMed:10433496 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A: Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol. 1996 Oct;48(10):1083-9. [PubMed:8953513 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23